Pharmaceuticals
Company Overview of Galileo Pharmaceuticals, Inc.
Company Overview
Galileo Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule therapeutics to treat metabolic and inflammatory diseases. The company is developing a pipeline of treatments for diabetes and arthritis. The company was formerly known as Galileo Laboratories, Inc. and changed its name to Galileo Pharmaceuticals, Inc. in April, 2003. The company was founded in 1997 and is headquartered in Santa Clara, California.
5301 Patrick Henry Drive
Santa Clara, CA 95054
United States
Founded in 1997
Phone:
408-654-5830
Fax:
408-654-5831
Key Executives for Galileo Pharmaceuticals, Inc.
Similar Private Companies By Industry
| Company Name | Region |
| Bio-Kinetic Clinical Applications, Inc. | United States |
| Bach Pharma, Inc. | United States |
| Phasex Corporation | United States |
| Mylan Pharmaceuticals Inc. | United States |
| FlowMetric, Inc. | United States |
Recent Private Companies Transactions
| Type Date |
Target | |
| No transactions available in the past 12 months. | ||
Most Searched Private Companies
| Company Name | Geographic Region |
| Bertelsmann AG | Europe |
| Lawyers Committee for Civil Rights Under Law | United States |
| NYC2012, Inc. | United States |
| Rush University | United States |
| Citizens Budget Commission | United States |
Post a JobJobs
- Greenville, NC | Vidant Medical CenterPosted: May 15
- New Brunswick, NJ | Tridiagonal SolutionsPosted: Apr 24
- Field, KY | Shire PharmaceuticalsPosted: May 18
- Field, KY | Shire PharmaceuticalsPosted: May 18
Sponsored Financial Commentaries
Sponsored Links
To contact Galileo Pharmaceuticals, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
